Why retaining empty containers helps resolve stability issues:

Packaging materials play a critical role in the stability of pharmaceutical products. If unexpected results arise—such as impurity spikes, potency loss, or moisture ingress—having retained reference containers from the same packaging lot can aid in identifying whether the issue is related to the packaging material or sealing integrity. These empty containers act as control samples for comparison in root cause investigations, reducing guesswork and improving resolution timelines.

Risks of not retaining packaging components:

Without retained reference containers:

• Root cause investigations may rely on indirect assumptions
• Issues such as poor sealing, delamination, or closure failures may go unverified
• Repeat incidents may occur if packaging flaws aren’t identified early
• Regulatory reviewers may question the completeness of your packaging evaluation

Maintaining a stock of representative empty containers ensures readiness for timely and evidence-based problem-solving.

Regulatory and Technical Context:

ICH and WHO perspectives on container-closure relevance:

ICH Q1A(R2) emphasizes the need to assess all aspects of container-closure systems in stability programs. WHO TRS 1010 reiterates the importance of demonstrating that packaging materials do not negatively impact product quality over time. CTD Modules 3.2.P.2, 3.2.P.7, and 3.2.P.8.3 all reference packaging integrity and compatibility. Regulatory bodies expect well-documented systems to track and investigate packaging-related stability failures.

Audit triggers and expectations:

Auditors may ask:

• If container lots are traceable to specific stability studies
• What material characterization was performed on retained samples
• How packaging-related deviations were investigated using retained samples

Lack of physical references can limit the effectiveness of CAPA and weaken regulatory confidence in packaging controls.

Best Practices and Implementation:

Define retention requirements in stability SOPs:

Establish procedures to:

• Retain a set number of empty containers (e.g., 3–5 units) per packaging lot
• Include closures, labels, induction seals, and blister films as applicable
• Label and store these samples under controlled conditions (e.g., ambient, secure)

Ensure QA oversight and documentation within the stability program master file or packaging control records.

Use retained containers in failure investigations:

Apply retained samples to:

• Compare sealing profiles or torque characteristics
• Assess material degradation under stress conditions
• Perform extractable or FTIR analysis if contamination is suspected

Document findings and compare against affected batch packaging to identify discrepancies or trends.

Link retained packaging to regulatory documentation:

Reference retained containers in:

• Deviation and CAPA reports for packaging issues
• APQR or product quality review summaries
• Packaging development and compatibility studies (CTD 3.2.P.7)

Store long-term alongside stability study documentation to support regulatory audits and lifecycle reviews.

Retaining empty container samples is a simple yet powerful strategy to support stability-related investigations. It enhances troubleshooting speed, reinforces your packaging control system, and provides a proactive foundation for ensuring long-term product integrity.

What are leachables and migratables?

Leachables are substances that migrate into a drug product from its container or closure system during storage, while migratables refer more broadly to all substances that can be transferred from the packaging under real use or storage conditions. These substances may arise from inks, adhesives, rubber stoppers, or plasticizers and can compromise product quality, safety, and efficacy. Including their evaluation in stability programs is essential to ensure compatibility over the product’s shelf life.

Why this matters for pharmaceutical safety:

Without leachable and migratable testing:

• Undetected substances may pose toxicity risks
• Regulatory submissions may be rejected or delayed
• Unexpected impurities could exceed ICH Q3B limits
• Stability failures may be linked to packaging instead of formulation

Proactively assessing leachables protects patients and strengthens your product’s regulatory acceptance.

Regulatory and Technical Context:

ICH and WHO recommendations on container-closure compatibility:

ICH Q3B emphasizes the need to monitor degradation products, including those that may result from packaging interaction. WHO TRS 1010 and FDA guidance stress that the container-closure system should not affect product safety or efficacy throughout the shelf life. CTD Modules 3.2.P.2 and 3.2.P.7 must describe material compatibility, while Module 3.2.P.8.3 should summarize testing outcomes, including any leachable-related concerns.

Audit expectations and global regulatory standards:

Inspectors typically review:

• Leachables and extractables reports
• Toxicological risk assessments for detected species
• Justification for selecting specific packaging materials

Absence of these evaluations may result in data deficiencies, additional testing mandates, or shelf-life re-evaluation.

Best Practices and Implementation:

Begin with extractables testing and risk prioritization:

Start by:

• Conducting extractables studies under exaggerated conditions
• Identifying compounds using GC-MS, LC-MS, and ICP-MS
• Creating a leachables target list for routine monitoring

Prioritize risk based on dosage form (e.g., higher risk for injectables or inhalation products).

Perform leachables testing at real-time and accelerated intervals:

Include leachables testing:

• At initial (0M), intermediate (6M), and final (12M/24M) stability time points
• For all intended storage conditions (long-term, accelerated)
• On samples stored in final commercial packaging

Use validated analytical methods sensitive enough to detect trace levels of known or unknown leachables.

Document all findings and link to product safety profile:

Ensure:

• Toxicological thresholds (e.g., PDEs) are compared against observed levels
• Reports are reviewed and approved by QA and toxicology teams
• Results are archived and summarized in regulatory dossiers

Link findings to formulation and packaging development reports to demonstrate comprehensive risk control.

Integrating leachable and migratable testing into your stability study framework is vital for long-term product safety and global regulatory approval. It reflects a mature quality system and a science-driven approach to pharmaceutical risk management.

Why adsorption studies are critical in plastic packaging:

Plastic containers—such as LDPE, HDPE, or polypropylene bottles—are frequently used in pharmaceutical packaging due to their lightweight, flexibility, and cost-effectiveness. However, these materials can adsorb active pharmaceutical ingredients (APIs), preservatives, or excipients, leading to potency loss, formulation instability, or assay failure during stability studies. Adsorption studies help quantify the extent of interaction and ensure packaging does not compromise drug content over time.

Implications of ignoring adsorption behavior:

Without adsorption analysis:

• API concentrations may fall below specification during shelf life
• Preservatives may be sequestered, increasing microbial risk
• Stability failures may be misattributed to degradation rather than packaging interaction
• Regulatory bodies may challenge your container-closure suitability justification

Evaluating drug-plastic interactions ensures data reliability and supports a science-based shelf-life claim.

Regulatory and Technical Context:

Guidelines supporting packaging compatibility studies:

ICH Q1A(R2) and WHO TRS 1010 require that packaging materials be evaluated for their influence on product stability. Container-closure interaction studies—including adsorption, leaching, and permeability—must be addressed in CTD Module 3.2.P.2 and 3.2.P.7. EMA, FDA, and Health Canada expect robust justification that chosen packaging does not affect the quality, efficacy, or safety of the pharmaceutical product throughout its intended shelf life.

Regulatory queries and audit focus areas:

Inspectors may ask:

• What evidence supports the compatibility of plastic containers with your drug product?
• Has any potency loss been observed in long-term or accelerated studies?
• Were controls implemented to assess potential adsorption or interaction with preservatives?

Lack of adsorption testing may trigger requests for supplementary data or changes in packaging strategy.

Best Practices and Implementation:

Design adsorption studies using worst-case simulations:

Conduct:

• Static studies where product is stored in the plastic container without stress
• Dynamic studies simulating shaking or agitation during distribution
• Testing with various fill volumes to assess surface area-to-volume effects

Compare recovery of API, preservatives, or critical excipients against glass or non-reactive control containers.

Use sensitive analytical methods and monitor over time:

Employ validated methods (e.g., HPLC, GC-MS) to:

• Detect changes in assay and preservative levels
• Identify any binding-related impurities
• Assess concentration differences at multiple time points (e.g., 0M, 3M, 6M)

Correlate adsorption results with stability data trends to support conclusions.

Document findings in packaging and stability sections:

Include adsorption study results in:

• Container-closure justification (CTD 3.2.P.2 and 3.2.P.7)
• Stability protocol risk assessments
• Packaging development reports and QA review summaries

Retain all raw data and conclusions for audit and regulatory inspection purposes.

Performing adsorption studies on plastic containers ensures a thorough understanding of drug-material interactions, enabling better packaging decisions, stronger regulatory submissions, and more reliable product shelf-life claims.

Why visual inspection is critical in container-closure systems:

Visual assessment of packaging components is often the first indicator of underlying chemical instability or material interaction. Discoloration of caps, seals, stoppers, or vial interiors may signal oxidation, leachables migration, UV damage, or reactions between the product and packaging. Regular inspection of container-closure systems throughout stability ensures that these warning signs are not overlooked.

Potential causes of discoloration:

Color changes may result from multiple mechanisms including light exposure, polymer degradation, residual solvents, or API-excipient interactions. For instance, rubber stoppers may turn yellow or brown due to oxidation of antioxidants or sulfur cross-linkers. HDPE bottles may discolor if exposed to elevated humidity and heat. These issues, if not detected early, can escalate into product recalls or regulatory observations.

Regulatory and Technical Context:

ICH, WHO, and GMP expectations:

ICH Q1A(R2) requires evaluation of product appearance and packaging integrity during stability. WHO TRS 1010 emphasizes the importance of visually inspecting the container-closure system at each time point. GMP guidelines (e.g., 21 CFR Part 211.94, EU Annex 9) mandate the use of non-reactive, non-additive packaging and visual examination for defects or anomalies during routine testing.

Regulatory risk and documentation standards:

Auditors often review photographic records and visual inspection logs. If packaging discoloration is detected during a study or in the field without prior documentation or justification, it may trigger data integrity concerns or questions about compatibility testing. Discoloration may also suggest extractables/leachables concerns, especially for parenteral and inhalation products.

Best Practices and Implementation:

Include visual checks at every stability time point:

As part of each pull schedule, inspect all components—caps, stoppers, seals, labels, internal vial surfaces—for any discoloration or surface change. Document findings with photographs and descriptions. Compare with baseline images taken at time zero to detect subtle but progressive changes. Train analysts to recognize early signs and classify severity levels.

Include visual appearance as a separate parameter in your stability data summary and review any abnormal observations through QA.

Link discoloration to root cause analysis and mitigation:

If discoloration is observed, conduct a detailed investigation involving analytical testing of the affected areas. This may include FTIR, GC-MS for volatiles, or UV-Vis scanning. Determine whether the discoloration impacts product quality or originates from the environment, formulation, or packaging. Implement CAPA if issues are systemic or batch-specific.

Requalify packaging vendors if material inconsistencies are found or initiate extractable/leachable studies as required.

Reflect findings in protocol and regulatory documentation:

Include observations and their impact analysis in CTD Module 3.2.P.8.1 (Stability Summary) and highlight preventive measures in 3.2.P.7 (Container Closure). If discoloration is non-impactful but frequent, consider documenting it in labeling to manage visual expectations. Ensure that any such observations are traceable, risk-assessed, and clearly explained during audits.